Abstract: The present invention relates among other things to a composition comprising at least two (2) human BNP fragments, wherein each of the human BNP fragments of the composition are cross-linked to at least one of the other human BNP fragments of the composition.
Type:
Grant
Filed:
May 29, 2008
Date of Patent:
September 6, 2011
Assignee:
Abbott Laboratories
Inventors:
Huaiqin Wu, Gangamani S. Beligere, Reika L. Campbell
Abstract: An improved extractive reagent composition and method for extracting an immunosuppressant drug, such as sirolimus, tacrolimus or cyclosporine, from blood samples while yielding a test sample extract that has low vapor pressure and is compatible with immunoassay components. The inventive reagent composition comprises dimethyl sulfoxide (DMSO), at least one divalent metal salt and water. The sample extracts resulting from use of each of these combinations have low vapor pressure and are compatible with immunochemistry assays.
Type:
Grant
Filed:
July 21, 2006
Date of Patent:
February 8, 2011
Assignee:
Abbott Laboratories
Inventors:
Frank C. Grenier, Ryan F. Workman, Hina Syed, Salman Ali
Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.
Type:
Grant
Filed:
October 6, 2009
Date of Patent:
February 8, 2011
Assignee:
Abbott Laboratories
Inventors:
John R. Hackett, Jr., Julie Yamaguchi, Alan M. Golden, Catherine A. Brennan, Robert K. Hickman, Sushil G. Devare
Abstract: Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and/or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection.
Type:
Grant
Filed:
December 5, 2006
Date of Patent:
December 28, 2010
Assignee:
Abbott Laboratories
Inventors:
Bailin Tu, Joan D. Tyner, James W. Scheffel, Michael K. White, Jeffrey M. Werneke, Robert N. Ziemann, David J. Hawksworth, Mary S. Pinkus, Robin A. Gutierrez
Abstract: The present invention relates to antibodies that specifically bind to human BNP and immunoassays using said antibodies in the quantification of human BNP or a fragment of human BNP in a test sample.
Type:
Grant
Filed:
May 23, 2005
Date of Patent:
June 8, 2010
Inventors:
Jessie W. Shih, Joan D. Tyner, Matthew S. Matias, Mary S. Pinkus, Susan E. Brophy, David J. Dagfal, David J. Hawksworth, Bryan C. Tieman
Abstract: The present invention relates to a method of extracting tacrolimus in a test blood sample to use in a tacrolimus quantification assay. The method of the present invention extracts tacrolimus in non-precipitating, non-denaturing aqueous environment, avoiding cumbersome manual pretreatment procedures or the use of organic solvents. The method of the present invention permits full automation of tacrolimus quantification assays.
Abstract: The present invention relates to methods for making stable test samples that can be used in ligand-binding assays for measuring natriuretic peptides.
Type:
Grant
Filed:
November 5, 2007
Date of Patent:
March 9, 2010
Assignee:
Abbott Laboratories, Inc.
Inventors:
Robert G. Parsons, David J. Daghfal, Cherie A. Lipowsky, Ray A. Weigand, Judith A. Friese
Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.
Type:
Grant
Filed:
December 12, 2007
Date of Patent:
November 10, 2009
Assignee:
Abbott Laboratories, Inc.
Inventors:
John R. Hackett, Julie Yamaguchi, Alan M. Golden, Catherine A. Brennan, Robert K. Hickman, Sushil G. Devare
Abstract: Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention.
Type:
Grant
Filed:
December 12, 2007
Date of Patent:
November 10, 2009
Assignee:
Abbott Laboratories, Inc.
Inventors:
John R. Hackett, Jr., Julie Yamaguchi, Alan M. Golden, Catherine A. Brennan, Robert K. Hickman, Sushil G. Devare
Abstract: The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.
Abstract: The present invention relates to a method of extracting tacrolimus in a test blood sample to use in a tacrolimus quantification assay. The method of the present invention extracts tacrolimus in non-precipitating, non-denaturing aqueous environment, avoiding cumbersome manual pretreatment procedures or the use of organic solvents. The method of the present invention permits full automation of tacrolimus quantification assays.
Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
Type:
Grant
Filed:
September 14, 2004
Date of Patent:
May 12, 2009
Assignee:
Abbott Laboratories, Inc.
Inventors:
Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
Type:
Grant
Filed:
September 14, 2004
Date of Patent:
May 12, 2009
Assignee:
Abbott Laboratories, Inc.
Inventors:
Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
Type:
Grant
Filed:
September 14, 2004
Date of Patent:
May 12, 2009
Assignee:
Abbott Laboratories, Inc.
Inventors:
Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
Type:
Grant
Filed:
September 14, 2004
Date of Patent:
May 12, 2009
Assignee:
Abbott Laboratories, Inc.
Inventors:
Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
Type:
Grant
Filed:
September 14, 2004
Date of Patent:
May 12, 2009
Assignee:
Abbott Laboratories, Inc.
Inventors:
Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.
Type:
Grant
Filed:
September 14, 2004
Date of Patent:
May 5, 2009
Assignee:
Abbott Laboratories, Inc.
Inventors:
Sheng C. Lou, Jeffrey C. Hunt, John G. Konrath, Xiaoxing Qiu, James W. Scheffel, Joan D. Tyner
Abstract: The present invention relates to a stable liquid calibrator or control for use in ligand-binding assays wherein the calibrator or control comprises at least one human synthetic natriuretic peptide and has a pH of from about 4.0 to about 6.5 and remains stable when stored at temperatures of from about 2 to about 8°C. for a period of about twelve months.
Type:
Grant
Filed:
July 16, 2003
Date of Patent:
November 4, 2008
Assignee:
Abbott Laboratories, Inc.
Inventors:
Judith A. Friese, Matthew S. Matias, Ray A. Weigand
Abstract: The present invention relates to methods for making stable compositions, such as, but not limited to, test samples, that can be used in ligand-binding assays.
Type:
Grant
Filed:
November 24, 2003
Date of Patent:
November 6, 2007
Assignee:
Abbott Laboratories
Inventors:
Robert G. Parsons, David J. Daghfal, Cherie A. Lipowsky, Ray A. Weigand, Judith A. Friese